44:I[185,["/_next/static/chunks/08z4tkzvltetr.js","/_next/static/chunks/121~yigv24_j6.js","/_next/static/chunks/0a~e7k..h6jfc.js","/_next/static/chunks/0za7dr7c2y81~.js","/_next/static/chunks/03klviw01y.ih.js","/_next/static/chunks/0gx_3vy1-syt4.js","/_next/static/chunks/0i6hzvr84kc1r.js"],"SendEmailButton"] 46:I[63625,["/_next/static/chunks/08z4tkzvltetr.js","/_next/static/chunks/121~yigv24_j6.js","/_next/static/chunks/0a~e7k..h6jfc.js","/_next/static/chunks/0za7dr7c2y81~.js","/_next/static/chunks/03klviw01y.ih.js","/_next/static/chunks/0gx_3vy1-syt4.js","/_next/static/chunks/0i6hzvr84kc1r.js"],"AddToLibraryButton"] 47:I[29721,["/_next/static/chunks/08z4tkzvltetr.js","/_next/static/chunks/121~yigv24_j6.js","/_next/static/chunks/0a~e7k..h6jfc.js","/_next/static/chunks/0za7dr7c2y81~.js","/_next/static/chunks/03klviw01y.ih.js","/_next/static/chunks/0gx_3vy1-syt4.js","/_next/static/chunks/0i6hzvr84kc1r.js"],"ShareButton"] 48:I[58016,["/_next/static/chunks/08z4tkzvltetr.js","/_next/static/chunks/121~yigv24_j6.js","/_next/static/chunks/0a~e7k..h6jfc.js","/_next/static/chunks/0za7dr7c2y81~.js","/_next/static/chunks/03klviw01y.ih.js","/_next/static/chunks/0gx_3vy1-syt4.js","/_next/static/chunks/0i6hzvr84kc1r.js"],"ProcessEpisodeButton"] 49:I[45269,["/_next/static/chunks/08z4tkzvltetr.js","/_next/static/chunks/121~yigv24_j6.js","/_next/static/chunks/0a~e7k..h6jfc.js","/_next/static/chunks/0za7dr7c2y81~.js","/_next/static/chunks/03klviw01y.ih.js","/_next/static/chunks/0gx_3vy1-syt4.js","/_next/static/chunks/0i6hzvr84kc1r.js"],"SignupCTA"] 3d:["$","h1",null,{"className":"max-w-[22ch] font-display text-[clamp(32px,4.5vw,48px)] font-medium leading-[1.05] tracking-[-0.02em] text-[color:var(--fg-1)] text-balance","children":"From Pharma to AGI Hype, and Developing AI in Finance: Martin Shkreli’s Journey"}] 3e:["$","div",null,{"className":"flex flex-wrap items-center gap-x-4 gap-y-1 font-mono text-[12px] uppercase tracking-[0.1em] text-[color:var(--fg-3)]","children":[["$","time",null,{"dateTime":"2025-05-20T10:00:00.000Z","children":"May 20, 2025"}],["$","span",null,{"aria-hidden":true,"children":"·"}],["$","span",null,{"children":"01:30:19"}],false]}] 45:T541,

In this episode of Gradient Dissent, Lukas Biewald talks with Martin Shkreli — the infamous "pharma bro" turned founder — about his path from hedge fund manager and pharma CEO to convicted felon and now software entrepreneur. Shkreli shares his side of the drug pricing controversy, reflects on his prison experience, and explains how he rebuilt his life and business after being "canceled."

They dive deep into AI and drug discovery, where Shkreli delivers a strong critique of mainstream approaches. He also talks about his latest venture in finance software, building Godel Terminal “a Vim for traders", and why he thinks the AI hype cycle is just beginning. It's a wide-ranging and candid conversation with one of the most controversial figures in tech and biotech.

Follow Martin Shkreli on Twitter

Godel Terminal: https://godelterminal.com/

Follow Weights & Biases on Twitter

https://www.linkedin.com/company/wandb

Join the Weights & Biases Discord Server:

https://discord.gg/CkZKRNnaf3